[Are therapeutic LDL goals justified? Controversies between the European and American guidelines]

Area of Science:

• Cardiology
• Internal Medicine
• Pharmacology

Background:

• Dyslipidemia is a major risk factor for cardiovascular disease (CVD).
• Effective management of dyslipidemia is crucial for cardiovascular prevention strategies.
• Statins are the established standard for lowering serum cholesterol levels.

Purpose of the Study:

• To discuss key points of divergence in dyslipidemia treatment between American and European guidelines.
• To analyze the controversies surrounding current dyslipidemia management approaches.
• To provide a narrative review of guideline discrepancies.

Main Methods:

• Narrative review methodology.
• Analysis of current American and European dyslipidemia treatment guidelines.
• Synthesis of key controversial aspects in dyslipidemia management.

Main Results:

• Significant differences exist in recommendations between American and European guidelines for dyslipidemia treatment.
• Specific areas of divergence include treatment targets and therapeutic strategies.
• Statins remain central, but their application varies across guidelines.

Conclusions:

• The divergent guidelines present challenges for consistent clinical practice in dyslipidemia management.
• Further harmonization or clarification of recommendations may be needed.
• Understanding these controversies is vital for optimal cardiovascular risk reduction.